All News

nurses.jpg

Nursing Shortage Could Worsen Due to Limited Student Loans

d MedPage Today

In November, we reported on nursing groups that pushed back against a Trump administration proposal to de-list nursing as a professional degree for purposes of student borrowing. In this report, we look ahead to see what might happen as a result of the policy change.

Read Article
alveolar hemorrhage acute

Diffuse Alveolar Hemorrhage in Rheumatic Disease

d Jack Cush, MD

A retrospective, cross-sectional, single-center study of adult rheumatic disease patients with diffuse alveolar hemorrhage (DAH), demonstrates a high proportion have coexistent pulmonary infection and significant mortality risk. 

Read Article
APR Rheum and Inflammation Testing Cover

Rheumatoid & Inflammation Testing

d Jack Cush, MD

Master the dos and don'ts of ordering RF, CCP (ACPA), and inflammatory markers that could transform your diagnostic accuracy.

Read Article
lupus SLE

Subcutaneous Anifrolumab in SLE

d Jack Cush, MD

Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab. 

Read Article
Kick off with a powerhouse RA session! ⚡️ Drs. Elena Myasoedova, Kristen Demoruelle, & Jeffrey Sparks dive deep into: 📉 Mortality Trends 🧬 The Mucosal Hypothesis 🫁 Recent ILD Advances Ends with a live faculty Q&A. A can’t-miss for RA clinicians in 2026! 🩺 Registration https://t.co/Z9oOkAyWPK
Dr. John Cush RheumNow ( View Tweet)
PNAS/Yale researchers report on a mice model of RA, MIF-dependent, CD74+ memory T cells (normally very few) expand & incr in number in the inflammed joint. When MIF genes were deleted in a CIA model, arthritis was prevented. MIF-dependent, CD74+ T cells promote chronic synovitis. https://t.co/pdPIqtSCwG
Dr. John Cush RheumNow ( View Tweet)
2026 Resolutions (1.9.2026) Dr. Cush reviews the news, announcements and journal articles from this past week on RheumNow. More on Variable bendability, a better way to treat RA, and a novel advance for GLP1a in PsA; and 2026 Resolutions! https://t.co/DgY2trZGKA https://t.co/3ka4SDRnJO

Links:

Dr. John Cush RheumNow ( View Tweet)

US News & World Report - Top 10 jobs in the USA (growth, pay, security); the only HCP listings: #5: Physician Assistant: Median salary: $133,260; Unemployment 1.6%; 33,100 new jobs by 2034 #1: Nurse Practitioner: Median salary: $129,210; Unemployment 0.6%; 128,400 new jobs by https://t.co/5c2hVc4ooi

Dr. John Cush RheumNow ( View Tweet)

Geisinger. Medical Center (PA) has medical staff of nearly 1,800 and another 1,200 advanced practice providers (NPs, PAs, CRNAs, midwives). They offer specialized training (eg Advanced Practitioner Fellowship in Critical Care Medicine ) and have an Advanced Practice Nursing https://t.co/pCaPWe6niB

Dr. John Cush RheumNow ( View Tweet)

1 in 3 NPs and PAs switch specialties at least once in career; often without formal training in the specialty. Both "depend on MDs for mentorship and training". Hence AMA is opposed to Removing physician supervision or collaboration requirements” for nonphysician providers https://t.co/8RXL8zre0p

Dr. John Cush RheumNow ( View Tweet)
A 2 yr. old female pt reported w/ a a novel P435S gain-of-function variant in TLR7 (thought pathogenic in SLE) - pt dx w/ juvenile SLE, recurrent infection, and neuroinflammatory features. A review of 12 other TLR7 GOF variants revealed similar SLE associations. https://t.co/TGgKDQ0D7F
Dr. John Cush RheumNow ( View Tweet)
EasyJIA score - a tool developed to refer juvenile pts w/ MSK sxs for rheum referral. 342 pts, (18%) Dx w/ JIA. 8 variables (10 total points) includes large Jts, daily Sxs, JT swelling, activity precipitating, +squeeze test, bending IP Jts, limping/stiffness, SI Pain. You need 3 https://t.co/zcCRUkuqh8
Dr. John Cush RheumNow ( View Tweet)
ADJUST trial (248 JIA pts w/ Uveitis & inactive >6mos, either continued or weaned off adalimumab. ADA weaning resulted in more flares (68% vs 14%, mostly uveitis) w/ no protection from background DMARD Rx. Restarting ADA was mostly effective. https://t.co/ZWHfPl2UNl https://t.co/xodyrbaQOj

Links:

Dr. John Cush RheumNow ( View Tweet)
2025 Lancet review https://t.co/Qbwup6QxZK of Osteoarthritis did not mention/endorse Rx w/ platelet rich plasma (PRP) prompting several letters of protest. Read the authors response: Despite the popularity of PRP, there are few PBO controlled high quality studies to prove its https://t.co/7pCZV9CHfJ

Links:

Dr. John Cush RheumNow ( View Tweet)

NJ Senate (Senate Bill No. 3560) has voted to permite Physician Assistans to enter the Interstate Physician Assistant Licensure Compact, designed to streamline PA licensing to work in multiple states https://t.co/VE1DdWuFwM https://t.co/szJzShVAaz

Links:

Dr. John Cush RheumNow ( View Tweet)
FIBROSCANS in 60 RA pts on #MTX for 5 yrs w/ liver studies. Mean age = 39.5yrs, w/ Dz Dur 8.2 yrs, mean BMI 24.4 & MTX 12.5–25 mg for ~8 yrs (cum dose 6728mg). All had normal AST, ALT, APRI, Abd US; fibroscan score = 170 ((steatosis grade 0). Only 4(6.7 %) had mild, fibrosis https://t.co/OOctcfI1sT
Dr. John Cush RheumNow ( View Tweet)
Systematic review of Apremilast in soriasis and Psoriatic Arthritis: 28 RCTs involving 6825 patients. Efficacy ( PASI 75 and ACR 20) observed at APR 30 mg or 20 mg bid (RR > 2) & both doses did not affect CRP levels. GI side effx most common (see figure) https://t.co/YqfaWPvmTm https://t.co/z8PfJqp0CJ

Links:

Dr. John Cush RheumNow ( View Tweet)
DANFLU-2 RCT of 332 438 elderly (43 881 w/ diabetes) tested high (HD-IIV) vs standard dose SD-IIV) flu vaccine. HD-IIV signif. reduced cardioresp., CV, CHF, influenza, hospitalizations vs SD-IIV, irrespective of DM status. Similar results previously seen in a Canadian RA pop. https://t.co/GGZPThoHrs
Dr. John Cush RheumNow ( View Tweet)

QD Clinic: Tophi Tales: Management of Uncontrolled Gout Daric Mueller, PA-C and Andrew Sulich, MD, St. Clair Shores, MI, present this QD Clinic: Tophi Tales: Management of Uncontrolled Gout. This QD Clinic is presented as part of RheumNow's "Mission: APP Partners in Care" https://t.co/7JTbC0223I

Dr. John Cush RheumNow ( View Tweet)
GLP-1 Agonist plus IL-17 Inhibition in Obese Psoriatic Arthritis Lilly announced the topline results from its phase 3b "TOGETHER PsA" trial, showing that the combination use of ixekizumab (Taltz) and tirzepatide (Zepbound) was superior to IXE alone, yielding both significant https://t.co/8fOXWULH7w
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×